HSBC TUR.WAR.OP.END. NOVA/ DE000HS2L245 /
| 2024-05-17 9:35:17 PM | Chg.-0.1400 | Bid9:59:47 PM | Ask9:59:47 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 3.5200EUR | -3.83% | 3.5200 Bid Size: 20,000 |
3.5500 Ask Size: 20,000 |
Novo Nordisk | 94.163 USD | 2078-12-31 | Call |
GlobeNewswire
05-15
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire
05-14
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
05-07
Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference
GlobeNewswire
04-22
Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to...
GlobeNewswire
04-22
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire
04-22
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into cli...
GlobeNewswire
04-11
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire
04-02
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
03-28
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategi...
GlobeNewswire
03-27
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completio...
GlobeNewswire
03-25
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the ...
GlobeNewswire
03-18
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
03-15
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated...
GlobeNewswire
03-12
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program...
GlobeNewswire
03-12
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOA...
GlobeNewswire
03-11
FUJIFILM Diosynth Biotechnologies Appoints Richard McAvoy as Chief Financial Officer
GlobeNewswire
03-07
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...
GlobeNewswire
03-07
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Car...
